search
Back to results

Connected Solution of Assistance Dedicated to Caregivers and People With Alzheimer's Disease or Related Diseases (Lili smart)

Primary Purpose

Alzheimer Disease

Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Functionalities of the Lili Smart Solution activated
Functionalities of the Lili Smart Solution non activated
Sponsored by
Hospices Civils de Lyon
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Alzheimer Disease focused on measuring Alzheimer's disease and Related Disorders (ADRD), natural caregiver, non-medical connected device, caregiver's burden, anxiety, costs, quality of life, depressive symptoms, independence

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Caregiver inclusion's criteria :

  • Natural caregiver helping the patient at least 6h / week for activities of daily living (if more than one caregiver, only one "referent" caregiver will be involved);
  • Can be the caregiver of only one patient of the study.
  • Having the ability to follow the study at the discretion of the investigator;
  • Having agreed to participate in the study;
  • Affiliated to a social security scheme;

Patient Inclusion Criteria:

  • Diagnosis of Alzheimer's disease or related disease;
  • Living at home
  • Age ≥ 50 years
  • Mini Mental State Examination (MMSE): 16-24 (included) (light to moderate);
  • Affiliated to a social security scheme;
  • Having agreed to participate in the study;
  • Having the physical and psychic abilities to follow the study according to the appreciation of the investigator.

Exclusion Criteria:

Patients exclusion's criteria:

  • Known psychiatric disorders
  • Disabling motor and / or sensory impairment
  • Patient under guardianship

Sites / Locations

  • Hopital des CharpennesRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

Functionalities of the Lili Smart Solution activated

Functionalities of the Lili Smart Solution non activated

Arm Description

Lili Smart solution consists of an application for caregivers (web / mobile), a GSM watch worn by the patient, smart sensors placed at different locations of the patient's home and a support service 24 / 24 and 7/7.

Lili Smart watch worn by the participants and sensors placed at home with their functionalities inactivated. Absence of the web / mobile application.

Outcomes

Primary Outcome Measures

Caregiver's burden evolution
Natural caregiver's burden evolution after 6 months of follow-up. Natural caregiver's burden evolution after 6 months of follow-up. Assessement with the Zarit scale

Secondary Outcome Measures

Evolution of the caregiver's anxiety level
Evolution of the caregiver's anxiety level estimated with repeated measures with the Spielberger's State-Trait Anxiety Inventory (STAI Y-A / Y-B).
Evolution of the caregiver's depressive symptomatology
Evolution of the caregiver's depressive symptomatology estimated with repeated measures of the Beck Depression Inventory (BDI)
Evolution of the caregiver's quality of life
Evolution of the caregiver's quality of life estimated with repeated measures of the Quality of Life in Alzheilmer's Disease scale, caregiver version
Evolution of the patient's quality of life
Evolution of patient's quality of life estimated with repeated measures of the Quality of Life in Alzheilmer's Disease scale, patient version
Evolution of the patient's independence
Evolution of the patient's independence with repeated measures of the Instrumental Activities of Daily Life (IADL-E, 9 items).
Evolution of the caregiver's quality of life
Evolution of the caregiver's quality of life estimated with repeated measures of the Quality of Life with EQ-5D questionnaire (EuroQol Five Dimensions questionnaire).
Evolution of the patient's quality of life
Evolution of patient's quality of life estimated with repeated measures of the Quality of Life with EQ-5D questionnaire (EuroQol Five Dimensions questionnaire).
Number of falls
Number of times the patient has fallen after 1 month, 3 months and 6 months.
Number of run aways
Number of times the patient has ran away after 1 month, 3 months and 6 months.
Number of drugs prescribed to the caregiver and the patient
Evolution of the number of drugs prescribed to the caregiver and the patient at inclusion and after 6 months of follow-up.
Indirect medical costs and direct non-medical costs
Data for indirect medical costs and direct non-medical costs will be collected with the RUD LITE questionnaire and the Lyon CMRR's MEMORA database
Evaluation of the caregiver's adherence to the Lili Smart solution
Evaluation of the caregiver's adherence to the Lili Smart solution after 7 months of follow-up (1 month of observation phase then 6 months of intervention) estimated through data collected in Lili Smart databases (number of connections to the application).
Evaluation of patient's adherence to the Lili Smart solution
Evaluation of the patient's adherence to the Lili Smart solution after 7 months of follow-up (1 month of observation phase then 6 months of intervention) estimated through data collected in Lili Smart databases (number of hours when the watch is worn).
Caregiver's burden evolution
Natural caregiver's burden evolution after 3 months of follow-up. Assessement with the Zarit scale

Full Information

First Posted
September 12, 2017
Last Updated
March 12, 2018
Sponsor
Hospices Civils de Lyon
Collaborators
Lili smart
search

1. Study Identification

Unique Protocol Identification Number
NCT03295110
Brief Title
Connected Solution of Assistance Dedicated to Caregivers and People With Alzheimer's Disease or Related Diseases
Acronym
Lili smart
Official Title
Lili Smart Study - Connected Solution of Assistance Dedicated to Caregivers and People With Alzheimer's Disease or Related Diseases
Study Type
Interventional

2. Study Status

Record Verification Date
September 2017
Overall Recruitment Status
Unknown status
Study Start Date
February 13, 2018 (Actual)
Primary Completion Date
September 2019 (Anticipated)
Study Completion Date
September 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hospices Civils de Lyon
Collaborators
Lili smart

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Alzheimer's disease and related diseases (ADRD) are a major public health issue. In France, nearly 900,000 people have ADRD, which represents about 70% of dementia cases, and the expected prevalence for 2020 is 1.2 million. Patients with ADRD have cognitive, behavioral and functional impairments that lead to progressive impairment of quality of life and autonomy. Maintaining them at home depends predominantly on their caregivers, mainly family, spouse or child. By definition, the caregiver is "the person who provides partial or total support to an elderly dependent person or a person with a disability in the vicinity of the victim for the activities of daily life". The investment of caregivers is therefore both human and financial, representing a greater or lesser burden. This burden can significantly affect their quality of life. Indeed, studies have shown that caregivers suffer from depletion, anxiety, depression and sleep disorders resulting in a deterioration of their health, leading them to greater care consumption. They would be more prone to cardiovascular diseases and cancer. A review of the literature from 2009 examined 66 studies evaluating the contribution of various technologies targeting demented patients and their caregivers. Of these, only 10 dealt with independence at home and the well-being of the patient and his / her caregiver. The main limitations of these studies are the small samples (ranging from 1 to 6 patients), the degree of cognitive degradation (mainly moderately severe) and the lack of standardized assessment. Although new technologies promise powerful home-based solutions, studies evaluating their efficacy for patients with ADRD and their caregivers remain scarce and fragile at the level of evidence due to methodological biases.
Detailed Description
Description of the intervention: Lili Smart solution consists of an application for caregivers (web / mobile), a GSM watch worn by the patient, smart sensors placed at different locations of the patient's home and a support service 24 / 24 and 7/7. Objectives: The main objective is to evaluate the impact of the Lili Smart solution on the burden felt by caregivers of patients with ADRD at 3 months and at 6 months of follow-up. The secondary objectives are to evaluate the impact of the Lili Smart solution at 3 months and 6 months of follow-up on: The anxiety of the caregiver of the patient with ADRD; Depression of the caregiver of the patient with ADRD; The quality of life of the caregiver of the patient with ADRD; The quality of life of the patient with ADRD, The level of functional autonomy of the patient with ADRD. The risks associated with the functional decline (falls, run aways) of the patient with ADRD. In addition to the social impact measurement, the study aims to demonstrate the medico-economic impact of Lili smart solution as follow: The direct and indirect medical costs of the patient and the caregiver. Patient and caregiver adherence to the Lili Smart solution will also be assessed as a secondary objective. Methodology : This study is an interventional research on the human person meeting the definition 1 ° of article L1121-1 of the CSP and not relating to the products mentioned in article L. 5311-1 It is a randomized, controlled, single-blind, parallel-group, interventional, randomized, controlled trial in N = 60 patients and their primary caregiver with an observational phase (inactive device), and one interventional phase (activated device).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alzheimer Disease
Keywords
Alzheimer's disease and Related Disorders (ADRD), natural caregiver, non-medical connected device, caregiver's burden, anxiety, costs, quality of life, depressive symptoms, independence

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Functionalities of the Lili Smart Solution activated
Arm Type
Experimental
Arm Description
Lili Smart solution consists of an application for caregivers (web / mobile), a GSM watch worn by the patient, smart sensors placed at different locations of the patient's home and a support service 24 / 24 and 7/7.
Arm Title
Functionalities of the Lili Smart Solution non activated
Arm Type
Other
Arm Description
Lili Smart watch worn by the participants and sensors placed at home with their functionalities inactivated. Absence of the web / mobile application.
Intervention Type
Other
Intervention Name(s)
Functionalities of the Lili Smart Solution activated
Other Intervention Name(s)
Non-medical connected device (Lili Smart solution) with active functionalities
Intervention Description
Non-medical connected device (Lili Smart solution) activated : application for caregivers (web / mobile), GSM watch worn by the patient, smart sensors placed at different locations of the patient's home and a support service 24 /24 and 7/7.
Intervention Type
Other
Intervention Name(s)
Functionalities of the Lili Smart Solution non activated
Other Intervention Name(s)
Non-medical connected device (Lili Smart solution) with inactive functionalities
Intervention Description
Non-medical connected device (Lili Smart solution) with inactive functionalities : watch worn by the participants and sensors placed at home with their functionalities inactivated. Absence of the web / mobile application.
Primary Outcome Measure Information:
Title
Caregiver's burden evolution
Description
Natural caregiver's burden evolution after 6 months of follow-up. Natural caregiver's burden evolution after 6 months of follow-up. Assessement with the Zarit scale
Time Frame
6 months after randomization
Secondary Outcome Measure Information:
Title
Evolution of the caregiver's anxiety level
Description
Evolution of the caregiver's anxiety level estimated with repeated measures with the Spielberger's State-Trait Anxiety Inventory (STAI Y-A / Y-B).
Time Frame
3 months and 6 months after randomization
Title
Evolution of the caregiver's depressive symptomatology
Description
Evolution of the caregiver's depressive symptomatology estimated with repeated measures of the Beck Depression Inventory (BDI)
Time Frame
3 months and 6 months after randomization
Title
Evolution of the caregiver's quality of life
Description
Evolution of the caregiver's quality of life estimated with repeated measures of the Quality of Life in Alzheilmer's Disease scale, caregiver version
Time Frame
3 months and 6 months after randomization
Title
Evolution of the patient's quality of life
Description
Evolution of patient's quality of life estimated with repeated measures of the Quality of Life in Alzheilmer's Disease scale, patient version
Time Frame
3 months and 6 months after randomization
Title
Evolution of the patient's independence
Description
Evolution of the patient's independence with repeated measures of the Instrumental Activities of Daily Life (IADL-E, 9 items).
Time Frame
3 months and 6 months after randomization
Title
Evolution of the caregiver's quality of life
Description
Evolution of the caregiver's quality of life estimated with repeated measures of the Quality of Life with EQ-5D questionnaire (EuroQol Five Dimensions questionnaire).
Time Frame
3 months and 6 months after randomization
Title
Evolution of the patient's quality of life
Description
Evolution of patient's quality of life estimated with repeated measures of the Quality of Life with EQ-5D questionnaire (EuroQol Five Dimensions questionnaire).
Time Frame
3 months and 6 months after randomization
Title
Number of falls
Description
Number of times the patient has fallen after 1 month, 3 months and 6 months.
Time Frame
1 months, 3 months and 6 months after randomization
Title
Number of run aways
Description
Number of times the patient has ran away after 1 month, 3 months and 6 months.
Time Frame
1 months, 3 months and 6 months after randomization
Title
Number of drugs prescribed to the caregiver and the patient
Description
Evolution of the number of drugs prescribed to the caregiver and the patient at inclusion and after 6 months of follow-up.
Time Frame
at inclusion and at 6 months
Title
Indirect medical costs and direct non-medical costs
Description
Data for indirect medical costs and direct non-medical costs will be collected with the RUD LITE questionnaire and the Lyon CMRR's MEMORA database
Time Frame
6 months
Title
Evaluation of the caregiver's adherence to the Lili Smart solution
Description
Evaluation of the caregiver's adherence to the Lili Smart solution after 7 months of follow-up (1 month of observation phase then 6 months of intervention) estimated through data collected in Lili Smart databases (number of connections to the application).
Time Frame
7 months
Title
Evaluation of patient's adherence to the Lili Smart solution
Description
Evaluation of the patient's adherence to the Lili Smart solution after 7 months of follow-up (1 month of observation phase then 6 months of intervention) estimated through data collected in Lili Smart databases (number of hours when the watch is worn).
Time Frame
7 months
Title
Caregiver's burden evolution
Description
Natural caregiver's burden evolution after 3 months of follow-up. Assessement with the Zarit scale
Time Frame
3 months after randomization

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Caregiver inclusion's criteria : Natural caregiver helping the patient at least 6h / week for activities of daily living (if more than one caregiver, only one "referent" caregiver will be involved); Can be the caregiver of only one patient of the study. Having the ability to follow the study at the discretion of the investigator; Having agreed to participate in the study; Affiliated to a social security scheme; Patient Inclusion Criteria: Diagnosis of Alzheimer's disease or related disease; Living at home Age ≥ 50 years Mini Mental State Examination (MMSE): 16-24 (included) (light to moderate); Affiliated to a social security scheme; Having agreed to participate in the study; Having the physical and psychic abilities to follow the study according to the appreciation of the investigator. Exclusion Criteria: Patients exclusion's criteria: Known psychiatric disorders Disabling motor and / or sensory impairment Patient under guardianship
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Deborah Viricel
Phone
4 72 43 25 01
Ext
+33
Email
deborah.viricel@chu-lyon.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Romain Bachelet
Phone
4 72 43 22 25
Ext
+33
Email
romain.bachelet@chu-lyon.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pierre Krolak-Salmon, MD
Organizational Affiliation
Hospices Civils de Lyon
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hopital des Charpennes
City
Villeurbanne
ZIP/Postal Code
69100
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pierre Krolak Salmon, Pr

12. IPD Sharing Statement

Learn more about this trial

Connected Solution of Assistance Dedicated to Caregivers and People With Alzheimer's Disease or Related Diseases

We'll reach out to this number within 24 hrs